Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 372

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Open access
Reeder, C B, Reece, D E, Kukreti, V, Chen, C, Trudel, S, Hentz, J, Noble, B, Pirooz, N A, Spong, J E, Piza, J G, Zepeda, V H J, Mikhael, J R, Leis, J F, Bergsagel, P L, Fonseca, R, Stewart, A K·2009·Leukemia
DOI 10.1038/leu.2009.26
Open this paper in CoChat — free account

Abstract

We have studied a three-drug combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed multiple myeloma (MM) patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m2 orally on days 1, 8, 15 and 22 and dexamethasone 40 mg orally on days 1–4, 9–12 and 17–20 on a 28-day cycle for four cycles. Responses were rapid with a mean 80% decline in the sentinel monoclonal protein at the end of two cycles. The overall intent to treat response rate (⩾ partial response) was 88%, with 61% of very good partial response or better (⩾VGPR) and 39% of complete/near complete response (CR/nCR). For the 28 patients who completed all four cycles of therapy, the CR/nCR rate was 46% and VGPR rate was 71%. All patients undergoing stem cell harvest had a successful collection. Twenty-three patients underwent stem cell transplantation (SCT) and are evaluable through day 100 with CR/nCR documented in 70% and ⩾VGPR in 74%. In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed MM with manageable toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2009.26

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 26

  1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy M, Hayman S, Buadi F et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520. · DOI · Paper page
  2. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164. · DOI · Paper page
  3. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526. · DOI · Paper page
  4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498. · DOI · Paper page
  5. Weber D . Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003; 10: 375–383. · DOI
  6. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer S, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053. · DOI · Paper page
  7. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367: 825–831. · DOI · Paper page
  8. Wang M, Weber DM, Delasalle K, Alexanian R . Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79: 194–197. · DOI
  9. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115–3121. · DOI · Paper page
  10. Lacy MQ, Gertz MA, Dispenzieri A, Hayman S, Geyer S, Kabat B et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179–1184. · DOI
  11. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783. · DOI · Paper page
  12. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R . Bortezomib in combination with thalidomide–dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235–239. · DOI
  13. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185. · DOI · Paper page
  14. Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece D et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005; 80: 1578–1582. · DOI
  15. Reece DE, Piza Rodriguez G, Chen C, Trudel S, Kukreti V, Mikhael J et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26: 4777–4783. · DOI
  16. Blade J, Sampson D, Reece D, Apperley J, BJOrkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123. · DOI · Paper page
  17. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473. · DOI · Paper page
  18. Rajkumar SV, Durie BG . Eliminating the complete response penalty from myeloma response criteria. Blood 2008; 111: 5759–5760. · DOI
  19. Greipp PR, San Miguel J, Durie BG, Crowley J, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420. · DOI · Paper page
  20. Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–145. · DOI
  21. Gertz MA, Lacy MQ, Inwards DJ, Pineda A, Chen M, Gastineau D et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375–380. · doi:10.1038/sj.bmt.1700897
  22. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda V, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282–1284. · DOI
  23. Attal M, Harousseau JL . Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 133–146. · doi:10.1016/s0889-8588(05)70419-6
  24. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294. · DOI · Paper page
  25. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441. · DOI · Paper page
  26. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood 2008; 112: 3107–3114. · DOI · Paper page

Cited by

See all 372

Metadata

Authors
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., Zepeda, V. H. J., Mikhael, J. R., Leis, J. F., Bergsagel, P. L., Fonseca, R., & Stewart, A. K.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2009-02-19
Volume
23
Issue
7
Pages
1337-1341
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
DOI
10.1038/leu.2009.26
OpenAlex
W2015003025
Cited by
372
References
7
FWCI
18.82
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. https://app.cochat.ai/papers/10.1038/leu.2009.26
The paper
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., Zepeda, V. H. J., Mikhael, J. R., Leis, J. F., Bergsagel, P. L., Fonseca, R., & Stewart, A. K. (2009). Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. https://doi.org/10.1038/leu.2009.26

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.